한빛사 논문
Jeongha Mok1, Hyungseok Kang2, Won-Jung Koh3, Byung Woo Jhun3, Jae-Joon Yim4, Nakwon Kwak4, Taehoon Lee5, Bohyoung Kang6 and Doosoo Jeon7,*
1Dept of Internal Medicine, Pusan National University Hospital, Pusan National University College of Medicine, Busan, South Korea
2Dept of Chest Medicine, Masan National Tuberculosis Hospital, Masan, South Korea
3Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
4Division of Pulmonary and Critical Care Medicine, Dept of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
5Dept of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
6Dept of Internal Medicine, Dong-A University Hospital, Busan, South Korea
7Dept of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University College of Medicine, Yangsan, South Korea
*For correspondence : Doosoo Jeon, Dept of Internal Medicine, Pusan National University Yangsan Hospital, 20 Geumo-ro, Yangsan 50612, South Korea.
Abstract
A phase III trial of delamanid showed acceptable safety and tolerability; however, it failed to demonstrate superior efficacy of delamanid in terms of reduction in time to sputum conversion and improvement in final treatment outcomes compared with placebo [1]. How to interpret these results and identify the role of delamanid in multidrug-resistant tuberculosis (MDR-TB) treatment is challenging [2]. Despite the disappointing results, this trial suggests that more studies are needed to better understand the role of delamanid in the current management of MDR-TB. So far, there have been several reports of real-world data on the interim outcomes of delamanid treatment [3–6], but few on its final outcomes [7].
논문정보
관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기